Research Information System
INTERNATIONAL OPHTHALMOLOGY, vol.36, no.4, pp.531-539, 2016 (SCI-Expanded)
To investigate the efficacy of single-dose intravitreal dexamethasone implantation in the treatment of persistent diabetic macular edema (DME) unresponsive to 3 consecutive ranibizumab injections over a period of 6 months. Forty-one patients with a previous history of treatment for DME including at least three consecutive intravitreal ranibizumab injections were enrolled in this retrospective study. Main outcome measures were change in best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure from baseline to 6th month. At the baseline, the mean CMT was 572.4 +/- A 123.1 mu m which improved to 264.2 +/- A 114.4, 317.7 +/- A 141.7, 410.6 +/- A 169.1, and 382.8 +/- A 181.5 mu m at the 1st, 3rd, 5th, and 6th month, respectively (p < 0.05). The preoperative mean BCVA was 0.85 +/- A 0.54 logMAR units which improved to 0.76 +/- A 0.5 (p = 0.08), 0.69 +/- A 0.4 (p = 0.02), 0.74 +/- A 0.4 (p = 0.284), and 0.72 +/- A 0.3 (p = 0.489) logMAR units at the 1st, 3rd, 5th, and 6th months, respectively. Additional injections were required for 13 (31 %) eyes at 3rd month and 14 (34 %) eyes at 5th month due to recurrence of macular edema. Intravitreal dexamethasone implantation caused a significant improvement of BCVA and reduction of CMT in the patients with persistent DME that were unresponsive to 3 consecutive ranibizumab injections. However, retreatment before 6 months in the majority of the patients was needed despite the beneficial effects after the index procedure.